MCP
RVNC

Mirador Capital Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Mirador Capital Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-72,355
Closed -$186K – 201
2024
Q2 		$186K Buy
+72,355
New +$247K 0.04% 180

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Mirador Capital Partners's RVNC Position: Q3 2024 in Review

Mirador Capital Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 72,355 shares — an estimated $186K sold.

Mirador Capital Partners first reported a position in RVNC in Q2 2024 and held it in 1 quarter. The position peaked at $186K in Q2 2024. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Mirador Capital Partners reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Mirador Capital Partners sold 72,355 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $186K.
  • Mirador Capital Partners first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 1 quarter.
  • Mirador Capital Partners's Revance Therapeutics, Inc. position peaked at $186K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Mirador Capital Partners's 13F filing for Q3 2024, filed 4 Oct 2024.